Shots:

• Intellia to receive ~$184M/product in development & commercial milestone along with royalties & gets an option to co-develop & co-commercialize ~2 products with commercialization rights in the US
• ONK gets a non-exclusive license to Intellia’s ex vivo CRISPR/Cas9-based genome editing platform & LNP-based delivery technologies along with an exclusive right to gRNAs for ~5 allogeneic CRISPR-edited NK cell therapies
• The collaboration will combine Intellia’s genome editing platform with ONK’s optimized NK cell therapy platform to develop NK cell-based cancer immunotherapy. ONK will lead the research, clinical development & commercialization of engineered NK cell therapies

 Ref: Globe Newswire | Image: Intellia